29/7 2019 07:00 Novartis provides update on Phase III PARAGON-HF trial in heart failure patients with preserved ejection fraction (HFpEF)
22/7 2019 07:15 Sandoz announces first patient enrolled in clinical study for proposed biosimilar denosumab in osteoporosis
16/7 2019 07:15 FDA accepts file and accelerates review of Novartis sickle cell disease medicine crizanlizumab (SEG101)
11/7 2019 22:30 Novartis, Amgen and Banner Alzheimer's Institute discontinue clinical program with BACE inhibitor CNP520 for Alzheimer's prevention
1/7 2019 17:30 Novartis successfully completes acquisition of Xiidra®, bolstering ophthalmic portfolio
12/6 2019 07:20 Cosentyx® provides long-lasting inhibition of radiographic progression in psoriatic arthritis, new Novartis data show
12/6 2019 07:15 Novartis Cosentyx® first to show efficacy in all key manifestations of psoriatic arthritis
4/6 2019 19:00 Long-term survival benefit shown for metastatic melanoma patients treated with Novartis Tafinlar® + Mekinist®
1/6 2019 13:30 Novartis Kisqali significantly extends life in women with HR+/HER2- advanced breast cancer in MONALEESA-7 trial
24/5 2019 18:42 AveXis Announces Innovative Zolgensma® Gene Therapy Access Programs for US Payers and Families
24/5 2019 18:30 AveXis receives FDA approval for Zolgensma®, the first and only gene therapy for pediatric patients with spinal muscular atrophy (SMA)
23/5 2019 07:15 Novartis highlights company transformation, catalyst-rich pipeline, and strong progress on strategy at Meet Novartis Management investor event
16/5 2019 15:00 Novartis data at ASCO and EHA demonstrate novel approaches to reimagining medicine in cancer and serious blood disorders